Harvard Bioscience Inc. (HBIO) intrinsic value & 10-year financials
Harvard Bioscience Inc. (HBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 2.1% a year to $86.5M, with an average return on invested capital of -7.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $8.09
- Market cap
- $359.1M
- Revenue (FY2025)
- $86.5M
- Revenue growth (10-yr CAGR)
- -2.1%
- ROIC (10-yr avg)
- -7.5%
- Free cash flow (FY2025)
- $5.5M
HBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $86.5M | -$56.7M | -$1.28 | $5.5M | -56.1% | -63.8% |
| FY2024 | $94.1M | -$12.4M | -$0.28 | -$1.2M | -6.6% | -5.8% |
| FY2023 | $112.2M | -$3.4M | -$0.08 | $12.2M | 1.7% | 1.6% |
| FY2022 | $113.3M | -$9.5M | -$0.23 | -$438.0K | -6.1% | -5.5% |
| FY2021 | $118.9M | -$288.0K | — | $67.0K | 1.7% | 1.6% |
| FY2020 | $102.1M | -$7.8M | — | $8.2M | 0.2% | 0.2% |
| FY2019 | $116.2M | -$4.7M | -$0.12 | $6.8M | 0.3% | 0.2% |
| FY2018 | $120.8M | -$2.9M | -$0.08 | $1.9M | 0.8% | 0.5% |
| FY2017 | $101.9M | -$865.0K | -$0.02 | $167.0K | -0.1% | -0.1% |
| FY2016 | $104.5M | -$4.3M | -$0.13 | — | -2.9% | -3.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
HARVARD BIOSCIENCE INC is facing top-line stagnation, with revenue contracting over the decade.
HARVARD BIOSCIENCE INC has historically struggled to out-earn its cost of capital, averaging just -7.5% ROIC.
Over the decade, HARVARD BIOSCIENCE INC shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, HARVARD BIOSCIENCE INC is modeled at -2.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.81 per share.